Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3556)	6/19/2018 11:35:29 AM
From: tuck	Respond to of 3661

Also, given the implications for Translarna, PTCT is down 15+% now. Good thing they have another program! Cheers, Tuck

To: Miljenko Zuanic who wrote (3556)	6/19/2018 11:54:28 AM
From: quidditch	Respond to of 3661

yes, congrats to SRPT holders: as long as Tuck injected SRPT in his firesale thread and also noted a firesale because of SRPT's results, a further question, albeit probably better suited for Peter's thread directly: Obviously, FGEN's 3019 MOA vs CCN2 is an entirely distinct MOA and approach from SRPT's GT, should the latter be considered as primary therapy (assuming development continues to be positive) or will DMD practitioners advocate pamrevlumab therapy in conjunction? That is to ask whether it is likely the two approaches can be used in complementary fashion? Too early on either account to posit?